Pegasys/Copegus combo pack clears FDA
Roche will continue to sell Pegasys (peginterferon alpha-2a) and Copegus (ribavirin) separately following FDA's June 4 approval of a co-packaged version. Roche is not announcing a launch date or pricing information for the combination. Availability of a co-packaged product could lessen the likelihood that patients will combine Pegasys with generic equivalents to Schering-Plough's Rebetol (ribavirin) (1"The Pink Sheet" April 12, 2004, p. 38)...
You may also be interested in...
Three Rivers/Par, Sandoz and Schering-Plough are launching their ribavirin generics at a 10% discount to Schering's Rebetol
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.